Similar articles

• US Food and Drug Administration regulatory oversight of laboratory-developed tests: Commentary on the draft guidance.

  Sidawy MK. Sidawy MK. Cancer Cytopathol. 2015 Oct;123(10):573-5. doi: 10.1002/cncy.21566. Epub 2015 Jun 4. Cancer Cytopathol. 2015. PMID: 26042383 No abstract available.
• FDA oversight of laboratory-developed tests will facilitate adoption of pharmacogenetic testing into routine clinical care.

  Hillebrenner E, Litwack E, Bradley P, Donigan K, Lowe T, Serrano K, Kelm K, Mansfield E, Gutierrez A. Hillebrenner E, et al. J Clin Pharmacol. 2015 Jul;55(7):728-30. doi: 10.1002/jcph.521. J Clin Pharmacol. 2015. PMID: 26053648 No abstract available.
• FDA's draft guidance on laboratory-developed tests increases clinical and economic risk to adoption of pharmacogenetic testing.

  Levy KD, Pratt VM, Skaar TC, Vance GH, Flockhart DA. Levy KD, et al. J Clin Pharmacol. 2015 Jul;55(7):725-7. doi: 10.1002/jcph.492. J Clin Pharmacol. 2015. PMID: 26053647 Free PMC article. No abstract available.
• Understanding the Food and Drug Administration's Jurisdiction Over Laboratory-Developed Tests and Divisions Between Food, Drug, and Cosmetic Act-Regulated and Clinical Laboratory Improvement Amendments of 1988-Regulated Activities.

  Thompson BM, Scott BI, Boiani JA. Thompson BM, et al. Clin Lab Med. 2016 Sep;36(3):575-85. doi: 10.1016/j.cll.2016.05.005. Epub 2016 Jun 30. Clin Lab Med. 2016. PMID: 27514469 Review.
• Laboratory-Developed Tests: A Legislative and Regulatory Review.

  Genzen JR, Mohlman JS, Lynch JL, Squires MW, Weiss RL. Genzen JR, et al. Clin Chem. 2017 Oct;63(10):1575-1584. doi: 10.1373/clinchem.2017.275164. Epub 2017 Jul 7. Clin Chem. 2017. PMID: 28687634 Review.